Javits Neuroscience Investigator Award Extension Request (Type 4 Clinical Trial Optional) | PAR 23 022

Opportunity Information: Apply for PAR 23 022

The Javits Neuroscience Investigator Award Extension Request (PAR-23-022) is a National Institutes of Health grant opportunity administered by the National Institute of Neurological Disorders and Stroke (NINDS). It supports a very specific purpose: it allows investigators who already hold an active NINDS Javits Neuroscience Investigator Award (an R37) to apply for the second segment of that award, extending their support beyond the initial period. The Javits program is designed for investigators with an established record of exceptional scientific accomplishment and unusually high research productivity, and it is structured to provide longer-term stability than a typical research project award.

The core goal of the Javits R37 mechanism is to provide up to seven total years of funding split into two phases. The first phase can last up to four years, and the second phase can add up to three additional years. This particular announcement is only about that second phase. In other words, it is not a general competition for new Javits awards, and it is not meant for investigators who are not already current NINDS Javits recipients. It is essentially an extension request pathway that enables eligible awardees to continue their research program with sustained support, assuming they meet NINDS expectations for continued outstanding performance and progress.

A notable administrative note embedded in the announcement states that NIH Institutes and Centers (ICs) should not join this opportunity and that the relevant submission route is a "Type 4" action intended specifically for NS (NINDS) R37 applications. The listing also indicates "Clinical Trial Optional," meaning the proposed work may include a clinical trial but does not have to; the key point is that the application must fit within the scope and requirements of the NINDS R37 Javits extension request framework.

Eligibility in the posting is presented broadly, reflecting the standard range of organizational applicants that NIH can fund, such as public and private institutions of higher education, nonprofit and for-profit entities (excluding small business restrictions in this listing), small businesses, and various levels of government. The announcement also explicitly names a wide range of institution types that may apply when otherwise eligible, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, tribal governments and organizations (including those other than federally recognized), faith-based and community-based organizations, U.S. territories and possessions, and even non-U.S. (foreign) entities and regional organizations. Practically, though, the controlling constraint is not the organizational category; it is the requirement that the applicant be a currently funded NINDS Javits (R37) recipient seeking the second phase of the same award.

From a classification standpoint, this is a discretionary grant opportunity in the health funding activity category, associated with CFDA number 93.853. The original closing date listed is 2025-09-15, and the opportunity was created on 2022-08-15. The award ceiling and expected number of awards are not specified in the provided source data, which is common for continuation/extension-style announcements where funding levels depend heavily on the existing award structure, institute budgets, and the specifics of the requested extension.

Overall, this opportunity functions as a continuation gateway for a select group of high-performing NINDS-supported investigators, offering the possibility of up to three more years of funding to maintain momentum, pursue longer-range scientific goals, and build on the productivity that originally justified the Javits designation.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Javits Neuroscience Investigator Award Extension Request (Type 4 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
• This funding opportunity was created on 2022-08-15.
• Applicants must submit their applications by 2025-09-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 23 022

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: